Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye…
Biotechnology
US, Waltham [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Viridian Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | -52.4600 | -334.125 | 4 | 2 | -7 | -14,953 | -6 | -2 | -6 | -2 | 7 | 169 |
| 2016 | -21.0000 | -13.950 | 2 | 3 | -11 | -624 | -11 | -3 | -11 | -3 | 10 | 274 |
| 2017 | -17.5700 | -20.213 | 3 | 4 | -12 | -904 | -12 | -4 | -9 | -4 | 9 | 295 |
| 2018 | -20.6600 | -15.930 | 4 | 9 | -26 | -712 | -25 | -9 | -46 | -9 | 10 | 643 |
| 2019 | -16.5700 | -17.130 | 8 | 4 | -32 | -766 | -31 | -4 | -63 | -4 | 11 | 298 |
| 2020 | -20.3100 | -5.112 | 4 | 0.87 | -42 | -228 | -40 | 0.87 | -74 | 0.87 | 11 | 60 |
| 2021 | -31.2000 | -5.384 | 1 | 3 | -110 | -240 | -109 | -3 | -68 | -3 | 13 | 207 |
| 2022 | -6.6600 | -3.557 | 2 | 2 | -79 | -159 | -78 | -2 | -80 | -2 | 25 | 147 |
| 2023 | -3.9100 | -4.937 | 1 | 0.37 | -125 | -237 | -128 | 0.37 | -135 | 0.37 | 35 | 25 |
| 2024 | -5.3100 | -4.032 | 0.31 | 0.32 | -237 | -180 | -234 | 0.32 | -255 | 0.32 | 94 | 21 |
| 2025 | - | -4.169 | - | 0.23 | - | -184 | - | 0.23 | - | 0.23 | - | 16 |
| 2026 | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F111/td> | - | 2.F111 | - | 2.F111 |
| 2027 | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F121/td> | - | 1.F121 | - | 1.F121 |
| 2028 | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F131/td> | - | 0.F131 | - | 0.F131 |